Clear Street’s enGene Therapeutics Warrants ENGNW Stock Holding History

Clear Street’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$759	Hold	300	–	–	﹤0.01%	1050
2025 Q4	$888	Hold	300	–	–	﹤0.01%	875
2025 Q3	$213	Hold	300	–	–	﹤0.01%	797
2025 Q2	$246	Hold	300	–	–	﹤0.01%	634
2025 Q1	$180	Buy	300 +100	+50%	+$82	﹤0.01%	529
2024 Q4	$169	Hold	200	–	–	﹤0.01%	535
2024 Q3	$420	Hold	200	–	–	﹤0.01%	635
2024 Q2	$238	Sell	200 -4,800	-96%	-$15.4K	﹤0.01%	720
2024 Q1	$26K	Sell	5,000 -23,410	-82%	-$71.3K	﹤0.01%	277
2023 Q4	$24.1K	Buy	+28,410	New	+$21.8K	﹤0.01%	252

Other funds holding ENGNW

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Clear Street's ENGNW Position: Q1 2026 in Review

Clear Street held its enGene Therapeutics Warrants (ENGNW) position steady in Q1 2026 at 300 shares worth $759. The position accounts for ﹤0.01% of the portfolio, ranked #1050.

Clear Street first reported a position in ENGNW in Q4 2023 and has held it in 10 quarters since. The position peaked at $26K in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

Clear Street held 300 shares of enGene Therapeutics Warrants worth $759 as of Q1 2026.
Clear Street left its enGene Therapeutics Warrants share count unchanged in Q1 2026.
enGene Therapeutics Warrants made up ﹤0.01% of Clear Street's portfolio in Q1 2026, its #1050 holding.
Clear Street first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 10 quarters since.
Clear Street's enGene Therapeutics Warrants position peaked at $26K in Q1 2024.
11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on Clear Street's 13F filing for Q1 2026, filed 15 May 2026.